Policy

ED law enforcement interactions affect survivors of violence and immigrant patients, emphasizing training and advocacy.

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Patients undergoing lung or colon cancer surgery at rural hospitals that later closed had better outcomes after transfer to high-performing oncology centers.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

President Donald J. Trump's health care overhaul during the first year of his second term reshapes Medicaid, vaccine policies, and drug pricing.

The House voted to extend the insurance subsidies under the Affordable Care Act (ACA), but the bill could face problems in the Senate.

As the CDC shifts childhood vaccines to shared decision-making, new surveys show many Americans misunderstand what the policy means—and who it involves.

The CDC announced a significant change to the childhood immunization schedule that would reduce vaccine recommendations.

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

Explore the evolving landscape of drug pricing, reproductive rights, and health policy in 2025, featuring insights on SC pembrolizumab and RFK Jr's hearings.

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

Explore how patient experience data shapes regulatory drug decisions, enhancing the patient-focused drug development initiative for better treatment outcomes.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

Industry leaders discuss how policy, pricing, and innovation will shape the future of oncology care and patient access.

Leaders of OneOncology share how the managed services organization empowers independent oncology practices through advanced technology, clinical trials, and value-based care, enhancing patient-focused cancer treatment.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

A last-minute push to extend Affordable Care Act subsidies was stopped as GOP leadership prevented an expedited vote, leaving the future of the subsidies uncertain.

Medicaid’s Institution for Mental Diseases (IMD) rule bars federal funding for psychiatric facilities with more than 16 beds, but findings indicate that state waivers allowing treatment of serious mental illness in IMDs do not increase overall psychiatric hospitalizations.

Leaders describe how shared data, theranostics programs, and coordinated clinical trials support independent practices and advance value-based cancer care.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.